ketoconazole has been researched along with Acute Relapsing Multiple Sclerosis in 2 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketoconazole, known to inhibit not only CYP3A but also CYP4F2, was an inhibitor of fingolimod metabolism in HLM with an inhibition constant (K(i)) of 0." | 1.37 | CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. ( Borell, H; Jin, Y; Patten, CJ; Zimmerlin, A; Zollinger, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Y | 1 |
| Zollinger, M | 1 |
| Borell, H | 1 |
| Zimmerlin, A | 1 |
| Patten, CJ | 1 |
| Vasiliou, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage[NCT04088630] | Early Phase 1 | 28 participants (Actual) | Interventional | 2020-08-07 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ketoconazole and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Interactions; Fingolimod Hydrochloride | 2010 |
1 other study available for ketoconazole and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P | 2011 |